 | |
 | |
| Clinical data | |
|---|---|
| Pronunciation | /kəˈrɪprəˌziːn/ |
| Trade names | Vraylar, Reagila, Symvenu |
| Other names | RGH-188 |
| AHFS/Drugs.com | Monograph |
| License data | |
| Pregnancy category | |
| Routes of administration | By mouth |
| Drug class | Atypical antipsychotic |
| ATC code | |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Bioavailability | High |
| Protein binding | 91–97% |
| Metabolism | Liver viaCYP3A4 and to a lesser extentCYP2D6 |
| Metabolites | desmethylcariprazine, didesmethylcariprazine |
| Eliminationhalf-life | 2–4 days for parent drug, and 1–3 weeks for active metabolites |
| Excretion | Urine (21%),bile |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| IUPHAR/BPS | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C21H32Cl2N4O |
| Molar mass | 427.41 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Cariprazine, sold under the brand nameVraylar among others, is anatypical antipsychotic developed byGedeon Richter,[7] which is used in the treatment ofschizophrenia andbipolar disorder.[8] It is also prescribed as anadd-on treatment forbipolardepression[9] andmajor depressive disorder.[5] Cariprazine acts primarily as aD3 andD2 receptor partial agonist, with a preference for theD3 receptor. It is a partial agonist at the serotonin5-HT1A receptor and acts as an antagonist at5-HT2B and5-HT2A receptors.[10] It is takenby mouth.[5] The most prevalent side effects includenausea, mildsedation,fatigue, anddizziness. At higher dosages, there is an increased risk forrestlessness,insomnia, andtremors.[5]
Cariprazine was approved for medical use in the United States in September 2015.[11] It was approved as ageneric medication in 2022,[12] but is covered by patents until 2029.[13] Cariprazine was approved by theTGA for use inAustralia in 2020.[14] As of 2025, the cost of Cariprazine is generally around $50.00USD,[15] $30.60AUD[16] on the PBS and £80.36 in theUK when on theNHS.[17]
Cariprazine is used to treat patients withschizophrenia,schizoaffective disorder andmanic, depressive,[18] ormixed episodes associated withbipolar I disorder. In the United States it is approved forschizophrenia in adults, acute treatment of manic or mixed episodes associated withbipolar I disorder in adults and treatment of depressive episodes associated with bipolar I disorder (bipolar depression).[19][5][20]
Cariprazine consistently improved clinical severity across a spectrum of patients with bipolar disorder or schizophrenia - effectively reducing psychosis, anxiety, manic and depressive symptoms.[21][22][23] In Australia, the United Kingdom, and the European Union it is approved only for treatingschizophrenia.[4][6][24]
Side effects may first appear several weeks after starting cariprazine.[5] Cariprazine does not appear to impactprolactin levels, and unlike many other antipsychotics, does not increase theQT interval on theelectrocardiogram (ECG). In short term clinical trials,extrapyramidal effects,sedation,akathisia, nausea,headache, dizziness, vomiting,insomnia, anxiety, and constipation were observed. One review characterized the frequency of these events as "not greatly different from that seen in patient treated with placebo"[25] but a second called the incidence of movement-related disorders "rather high".[26][27]
Regarding these side effects, the label of cariprazine states, "The possibility of lenticular changes or cataracts cannot be excluded at this time."[5]
Because cariprazine and its active metabolites have long half-lives, many healthcare professionals monitor for adverse effects up to several weeks after starting cariprazine. A longer monitoring period is also indicated for dosage changes, whether they represent an increase or a decrease, because elimination may take several weeks.[28]
| Site | Ki (nM) | IA (%) | Action |
|---|---|---|---|
| 5-HT1A | 2.6 | ~40% | Partial agonist / functional antagonist |
| 5-HT2A | 18.8 | Inverse agonist | |
| 5-HT2B | 0.58 | Antagonist | |
| 5-HT2C | 134 | Inverse agonist | |
| 5-HT7 | 111 | Antagonist | |
| α1A | 155 | Antagonist | |
| D2L | 0.49 | ~30% | Partial agonist or functional antagonist |
| D2S | 0.69 | ~30% | partial agonist / Antagonist or functional full agonist[clarification needed] |
| D3L | 0.085 | ~70% | Partial agonist / functional full agonist |
| H1 | 23.2 | Antagonist | |
| mAChTooltip Muscarinic acetylcholine receptor | >1,000 | Antagonist | |
| The smaller the Ki value, the more strongly the drug binds to the site. IA=intrinsic activity. | |||
Unlike many antipsychotics that are D2 and 5-HT2Areceptor antagonists, cariprazine is a D2 and D3partial agonist. It also has a higher affinity for D3 receptors. The D2 and D3 receptors are important targets for the treatment of schizophrenia, because the overstimulation of dopamine receptors has been implicated as a possible cause of schizophrenia.[32] Cariprazine acts to inhibit overstimulated dopamine receptors (acting as an antagonist) and stimulate the same receptors when the endogenous dopamine levels are low. Cariprazine's high selectivity towards D3 receptors could prove to reduce side effects associated with the other antipsychotic drugs, because D3 receptors are mainly located in theventral striatum and would not incur the same motor side effects (extrapyramidal symptoms) as drugs that act ondorsal striatum dopamine receptors.[33] Cariprazine also acts on5-HT1A receptors, though the affinity is considerably lower than the affinity to dopamine receptors (seen in monkey and rat brain studies).[33][34] In the same studies, cariprazine has been noted to produce pro-cognitive effects, the mechanisms of which are currently under investigation. An example of pro-cognitive effects occurred in pre-clinical trials with rats: rats with cariprazine performed better in a scopolamine-induced learning impairment paradigm in awater labyrinth test. This may be due to the selective antagonist nature of D3 receptors, though further studies need to be conducted.[33] This result could be very useful for schizophrenia, as one of the symptoms includes cognitive deficits.
Cariprazine has partial agonist as well as antagonist properties depending on the endogenous dopamine levels. When endogenous dopamine levels are high (as is hypothesized in schizophrenic patients), cariprazine acts as an antagonist by blocking dopamine receptors. When endogenous dopamine levels are low, cariprazine acts more as an agonist, increasing dopamine receptor activity.[25] In monkey studies, the administration of increasing doses of cariprazine resulted in a dose-dependent and saturable reduction of specific binding. At the highest dose (300 μg/kg), the D2/D3 receptors were 94% occupied, while at the lowest dose (1 μg/kg), receptors were 5% occupied.[34] Dopamine D2 and D3 receptor occupancy in humans has been summarized as, "In healthy volunteers, single-dose cariprazine of 0.5 mg occupied up to 12% of striatal D2/D3 receptors, while striatal D2/D3 occupancy after multiple dosing up to cariprazine 1.0 mg/d ranged from 63 to 79% [39]. In an open-label, fixed-dose, 2-week trial in eight males with schizophrenia, PET scans of dorsal striatal regions (caudate nucleus and putamen) and ventral striatum (nucleus accumbens) showed maximum occupancy (‡ 90%) at a 3-mg target dose of cariprazine following 14 d of treatment [40,41]. After 14 d of cariprazine 1.5 mg/d, receptor occupancy was 69% in the caudate nucleus, 69% in the nucleus accumbens, and 75% in the putamen".[25]
Cariprazine, as well as other third generation antipsychotics, possesses a lower chance of exacerbating extrapyramidal symptoms. However the ability to induce akathasia remains relatively high. This may be mediated through a lack of anticholinergic effects (as agents ofthis class are sometimes used to treat akathisia), as well as a lack of a balanced dopaminergic(D2)/serotonergic(5-HT2A) ratio(compared to the second generation antipsychotics serving a more nuanced profile in this regard)[clarify].[35][36][37] Moreover, partial agonists, through their limited response triggering, ironically often have the tendency to occupy near all targeted receptors at relatively low dosages of the drug. An extreme example is aripiprazole with an average occupancy of 70% (D2) at a 2 mg dose, well below its usual antipsychotic dosage (the often cited threshold of occupancy for an antipsychotic effect is 70%). This could be another reason for akathasia from partial agonists.[38][39]
Partialagonists are drugs that bind to and activate specific receptors, but they produce a weaker response than fullagonists, even when all receptors are occupied. In neuronal signaling pharmacology, their activity is often described using two models: one considers how much of the drug binds to postsynaptic receptors, which can block stronger agonists from activating the receptor, while the other looks at how the drug can activate receptors by itself, but only to a limited extent compared to a full agonist. Partial agonists can act as both weak activators and blockers, depending on the presence of natural neurotransmitters likedopamine. When natural dopamine levels are high, partial agonists compete for the same receptors, reducing excessive signaling. When dopamine levels are low, partial agonists provide some activation, but not as much as dopamine or a full agonist would. The effectiveness of a partial agonist is often measured by theEC50 value, which is the concentration needed to produce half of its maximum possible effect. Drugs likearipiprazole, cariprazine, andbrexpiprazole are examples of partial agonists used as antipsychotics. They help stabilize mood and reduce psychotic symptoms by balancing dopamine activity in the brain.[40][41][42][43][circular reference]
Cariprazine has high oralbioavailability and can cross theblood brain barrier easily in humans because it is lipophilic.[44] In rats, the oral bioavailability was 52% (with a dose of 1 mg/kg).[27]
Cariprazine is metabolized primarily by thecytochrome P450 3A4 isoenzyme (CYP3A4), with some minor metabolism byCYP2D6. Cariprazine does not induce the production of CYP3A4 or CYP1A2 in the liver, and weakly, competitively inhibits CYP2D6 and CYP3A4.[19]
PositivePhase III study results were published forschizophrenia andmania in early 2012, and forbipolar disorder Idepression from aPhase II trial in 2015.[45][44]
Cariprazine is also potentially useful as anadd-on therapy inmajor depressive disorder.[46] It is being developed jointly byAbbVie andGedeon Richter Plc, with AbbVie responsible for commercialization in the US, Canada, Japan, Taiwan and certain Latin American countries (including Argentina, Bolivia, Brazil, Chile, Colombia, Ecuador, Mexico, Peru and Venezuela). In February 2022,AbbVie requested approval by the USFood and Drug Administration (FDA) for adjunctive treatment for major depressive disorder.[47] Approval was granted by the FDA in December 2022 for cariprazine to be used as an adjunctive treatment for major depressive disorder.[48]
